BLB 201
Alternative Names: BL-200 RSV; BLB-201; CPI-RSV-F Vaccine - Blue Lake Biotechnology; Intranasal RSV vaccine - Blue Lake Biotechnology; PIV5-vectored RSV vaccine - Blue Lake BiotechnologyLatest Information Update: 16 Sep 2025
At a glance
- Originator Blue Lake Biotechnology
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Respiratory syncytial virus infections
Most Recent Events
- 16 Sep 2025 Phase I development is ongoing in Respiratory-syncytial-virus-infections (In the elderly, Prevention, In adults) in USA (Intranasal, Spray) (Blue Lake Biotechnology pipeline, September 2025)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In the elderly, Prevention, In adults) in USA (Intranasal, Spray)
- 12 Dec 2024 Updated immunogenicity and adverse events data from a phase I/II trial in Respiratory syncytial virus infections released by Blue Lake Biotechnology